Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7050 PK Food Effect and Dose Escalation in Healthy Subjects
NCT02533102Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Golvatinib in solid tumor (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Time to Maximum Plasma Concentration, Maximum Observed Plasma Concentration and 4 more. Started Nov 2010; status: completed.
02
Drugs
Golvatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02533102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533102.